DOP2019000274A - Métodos y composiciones para el tratamiento de apnea del sueño - Google Patents
Métodos y composiciones para el tratamiento de apnea del sueñoInfo
- Publication number
- DOP2019000274A DOP2019000274A DO2019000274A DO2019000274A DOP2019000274A DO P2019000274 A DOP2019000274 A DO P2019000274A DO 2019000274 A DO2019000274 A DO 2019000274A DO 2019000274 A DO2019000274 A DO 2019000274A DO P2019000274 A DOP2019000274 A DO P2019000274A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compositions
- treatment
- methods
- sleep apnea
- nri
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491504P | 2017-04-28 | 2017-04-28 | |
| US201762558814P | 2017-09-14 | 2017-09-14 | |
| PCT/US2018/029518 WO2018200775A1 (en) | 2017-04-28 | 2018-04-26 | Methods and compositions for treating sleep apnea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2019000274A true DOP2019000274A (es) | 2019-12-30 |
Family
ID=63918622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2019000274A DOP2019000274A (es) | 2017-04-28 | 2019-10-25 | Métodos y composiciones para el tratamiento de apnea del sueño |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11123313B2 (enExample) |
| EP (1) | EP3615016A4 (enExample) |
| JP (3) | JP7373997B2 (enExample) |
| KR (3) | KR102682159B1 (enExample) |
| CN (2) | CN110799181A (enExample) |
| AU (3) | AU2018260666B2 (enExample) |
| BR (1) | BR112019022483A2 (enExample) |
| CA (1) | CA3061468A1 (enExample) |
| CO (1) | CO2019013180A2 (enExample) |
| CR (1) | CR20190546A (enExample) |
| DO (1) | DOP2019000274A (enExample) |
| EC (1) | ECSP19084058A (enExample) |
| GE (4) | GEAP202416602A (enExample) |
| MA (1) | MA49069A (enExample) |
| MX (2) | MX394941B (enExample) |
| MY (1) | MY200172A (enExample) |
| NI (1) | NI201900110A (enExample) |
| PH (1) | PH12019502427A1 (enExample) |
| SG (2) | SG10202111623TA (enExample) |
| UA (1) | UA127759C2 (enExample) |
| WO (1) | WO2018200775A1 (enExample) |
| ZA (1) | ZA201907158B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123313B2 (en) * | 2017-04-28 | 2021-09-21 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| CA3089712A1 (en) * | 2018-01-30 | 2019-08-08 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| CN108309261B (zh) * | 2018-02-11 | 2020-05-22 | 西安交通大学 | 一种猝死预警方法及装置和系统 |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| MX2021004883A (es) * | 2018-10-31 | 2021-08-05 | Apnimed Inc Delaware | Metodos y composiciones para tratar apnea del sue?o. |
| CA3129270A1 (en) | 2019-02-08 | 2020-08-13 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| CA3177654A1 (en) | 2020-05-05 | 2021-11-11 | Dennis MOLNAR | Polymorphic forms of (r)-oxybutynin hydrochloride |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| RU2757470C1 (ru) * | 2020-11-19 | 2021-10-18 | Ренат Рашитович Ахмеров | Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы |
| US20240075035A1 (en) * | 2021-01-14 | 2024-03-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| AU2022231133A1 (en) * | 2021-03-04 | 2023-09-21 | Apnimed, Inc. (Delaware) | Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea |
| US20240189328A1 (en) * | 2021-04-16 | 2024-06-13 | Apnimed, Inc. (Delaware) | Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea |
| BR112023026158A2 (pt) * | 2021-06-17 | 2024-03-05 | Apnimed Inc Delaware | Inibidores da recaptação de norepinefrina para tratamento da apneia do sono |
| CN117956959A (zh) * | 2021-08-31 | 2024-04-30 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CA3259605A1 (en) * | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
| CA3259602A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea |
| CN118475347A (zh) | 2021-12-22 | 2024-08-09 | 拜耳公司 | 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与降肾上腺素重摄取抑制剂的结合物 |
| EP4522149A1 (en) * | 2022-05-13 | 2025-03-19 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000071108A2 (en) | 1999-05-20 | 2000-11-30 | Sepracor Inc. | Methods for treatment of asthma using s-oxybutynin |
| NZ520975A (en) * | 2000-02-24 | 2004-03-26 | Upjohn Co | New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders |
| WO2006023703A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders |
| CN101132777A (zh) * | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| CN107007602A (zh) * | 2011-01-28 | 2017-08-04 | 辉达斯医学研究所 | 治疗阻塞性睡眠呼吸暂停的方法 |
| US11123313B2 (en) * | 2017-04-28 | 2021-09-21 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| CA3089712A1 (en) * | 2018-01-30 | 2019-08-08 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
-
2018
- 2018-04-26 US US16/609,048 patent/US11123313B2/en active Active
- 2018-04-26 CN CN201880042623.1A patent/CN110799181A/zh active Pending
- 2018-04-26 CR CR20190546A patent/CR20190546A/es unknown
- 2018-04-26 KR KR1020197034523A patent/KR102682159B1/ko active Active
- 2018-04-26 MX MX2019012729A patent/MX394941B/es unknown
- 2018-04-26 WO PCT/US2018/029518 patent/WO2018200775A1/en not_active Ceased
- 2018-04-26 CN CN202411366994.9A patent/CN119185558A/zh active Pending
- 2018-04-26 MA MA049069A patent/MA49069A/fr unknown
- 2018-04-26 CA CA3061468A patent/CA3061468A1/en active Pending
- 2018-04-26 GE GEAP202416602A patent/GEAP202416602A/en unknown
- 2018-04-26 BR BR112019022483-1A patent/BR112019022483A2/pt unknown
- 2018-04-26 UA UAA201910615A patent/UA127759C2/uk unknown
- 2018-04-26 EP EP18791670.5A patent/EP3615016A4/en active Pending
- 2018-04-26 SG SG10202111623TA patent/SG10202111623TA/en unknown
- 2018-04-26 MY MYPI2019006319A patent/MY200172A/en unknown
- 2018-04-26 JP JP2019558554A patent/JP7373997B2/ja active Active
- 2018-04-26 AU AU2018260666A patent/AU2018260666B2/en active Active
- 2018-04-26 KR KR1020257032249A patent/KR20250145704A/ko active Pending
- 2018-04-26 SG SG11201909973U patent/SG11201909973UA/en unknown
- 2018-04-26 KR KR1020247009759A patent/KR20240042261A/ko not_active Ceased
- 2018-04-26 GE GEAP201815226A patent/GEP20227387B/en unknown
- 2018-04-26 GE GEAP201815757A patent/GEP20247617B/en unknown
- 2018-04-26 GE GEAP201816320A patent/GEP20257788B/en unknown
-
2019
- 2019-10-24 MX MX2022010349A patent/MX2022010349A/es unknown
- 2019-10-25 PH PH12019502427A patent/PH12019502427A1/en unknown
- 2019-10-25 NI NI201900110A patent/NI201900110A/es unknown
- 2019-10-25 DO DO2019000274A patent/DOP2019000274A/es unknown
- 2019-10-29 ZA ZA2019/07158A patent/ZA201907158B/en unknown
- 2019-11-25 EC ECSENADI201984058A patent/ECSP19084058A/es unknown
- 2019-11-26 CO CONC2019/0013180A patent/CO2019013180A2/es unknown
-
2021
- 2021-09-10 US US17/471,892 patent/US20210401777A1/en not_active Abandoned
-
2022
- 2022-09-27 AU AU2022241471A patent/AU2022241471A1/en not_active Abandoned
-
2023
- 2023-06-30 JP JP2023108387A patent/JP2023139000A/ja active Pending
- 2023-07-19 US US18/355,178 patent/US20240189261A1/en not_active Abandoned
-
2024
- 2024-03-04 US US18/594,885 patent/US20240261239A1/en not_active Abandoned
-
2025
- 2025-07-31 JP JP2025128090A patent/JP2025169279A/ja active Pending
- 2025-09-11 AU AU2025230729A patent/AU2025230729A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000274A (es) | Métodos y composiciones para el tratamiento de apnea del sueño | |
| MX2025004365A (es) | Metodos y composiciones para el tratamiento de la apnea del sue?o | |
| CO2018005905A2 (es) | Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| DOP2019000171A (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| DOP2019000172A (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| CL2012002540A1 (es) | Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. | |
| CL2009002017A1 (es) | Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria. | |
| MY198201A (en) | A Combination Medicament Comprising Phenylephrine And Paracetamol | |
| CL2023002824A1 (es) | Métodos y composiciones para tratar la apnea del sueño | |
| EA201992569A1 (ru) | Способы и композиции для лечения апноэ во сне | |
| NZ758564B2 (en) | Methods and compositions for treating sleep apnea | |
| AR110417A1 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| MX2024007767A (es) | Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o. | |
| BR112014029577A2 (pt) | uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono | |
| CL2021001315A1 (es) | Antagonistas de los adrenoreceptores a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño | |
| Hui-min | Effect of dezocine analgesia on the incidence of the postoperative delirium in orthopedic patients | |
| CO7240357A2 (es) | Solución de acetaminofen supersaturada inyectable para la administración por la espina dorsal |